Bioequivalence

 If two medicines are bioequivalent there is no clinically significant difference in their bioavailability. Although bioequivalence is most commonly discussed in relation to generic medicines, it is important to note that bioequivalence studies are also performed for innovator medicines in some situations such as: between early and late clinical trial formulations or between the formulations used in clinical trials and the product to be marketed for new medicines when changes in formulation have occurred after an innovator product has been approved, for example a change in one or more excipients (inactive ingredients).

 

  • Pharmacokinetic Studies
  • Pharmacodynamic Studies
  • Clinical Studies
  • IVIVC
  • Earlier exposure on BE

Related Conference of Bioequivalence

December 14-14, 2020

2nd Pathology and Infectious Disease Conference

Dubai, UAE
March 28-29, 2021

11th Glycobiology World Congress

Vienna, Austria
April 24-24, 2021

2nd International Conference on Nucleic Acids

London, UK
June 11-12, 2021

25th Global Congress on Biotechnology

Berlin, Germany
September 13-14, 2021

17th World Congress on Structural Biology

Prague, Czech Republic
September 27-28, 2021

25th European Biotechnology Congress

Dublin, Ireland

Bioequivalence Conference Speakers

Recommended Sessions

Related Journals

Are you interested in